DOP2018000102A - Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih - Google Patents

Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih

Info

Publication number
DOP2018000102A
DOP2018000102A DO2018000102A DO2018000102A DOP2018000102A DO P2018000102 A DOP2018000102 A DO P2018000102A DO 2018000102 A DO2018000102 A DO 2018000102A DO 2018000102 A DO2018000102 A DO 2018000102A DO P2018000102 A DOP2018000102 A DO P2018000102A
Authority
DO
Dominican Republic
Prior art keywords
trivalent
prevention
treatment
proteins
specific
Prior art date
Application number
DO2018000102A
Other languages
English (en)
Inventor
Rao Ercole
Kruip Jochen
Qiu Huawei
Beil Christian
Beninga Jochen
Lange Christian
Yang Zhi-Yong
J Nabel Gary
Xu Ling
Wei Ronnie
Dirk Leuschner Wulf
Connors Mark
R Mascola John
A Koup Richard
Huang Jinghe
Zhou Tongqing
D Kwong Peter
Do Kwon Young
Pegu Amarendra
A Doria-Rose Nicole
Asokan Mangaiarkarasi
Original Assignee
Sanofi Sa
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Us Health filed Critical Sanofi Sa
Publication of DOP2018000102A publication Critical patent/DOP2018000102A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente memoria se proporcionan que comprenden proteínas de unión triespecíficas y/o trivalentes que comprenden cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas diana del VIH o uno o más receptores de células T, en donde un primer par de polipéptidos que forman la proteína de unión posee dominios variables duales que tienen una orientación cruzada y en donde un segundo par de polipéptidos que forman la proteína de unión posee un solo dominio variable. También se proporcionan en la presente memoria métodos para preparar proteínas de unión triespecíficas y/o trivalentes y usos de tales proteínas de unión para el tratamiento y/o la prevención de VIH/SIDA.
DO2018000102A 2015-10-25 2018-04-20 Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih DOP2018000102A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03

Publications (1)

Publication Number Publication Date
DOP2018000102A true DOP2018000102A (es) 2018-11-30

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000102A DOP2018000102A (es) 2015-10-25 2018-04-20 Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih

Country Status (30)

Country Link
US (4) US20190054182A1 (es)
EP (2) EP3819310A1 (es)
JP (3) JP7169190B2 (es)
KR (1) KR102687212B1 (es)
CN (4) CN116789841A (es)
AR (1) AR106466A1 (es)
AU (2) AU2016347058B2 (es)
BR (1) BR112018008011A2 (es)
CA (1) CA3002664A1 (es)
CL (1) CL2018001065A1 (es)
CO (1) CO2018005337A2 (es)
CR (1) CR20180288A (es)
DO (1) DOP2018000102A (es)
EA (1) EA201891028A1 (es)
ES (1) ES2894304T3 (es)
HR (1) HRP20211528T1 (es)
HU (1) HUE056608T2 (es)
IL (2) IL301140A (es)
MA (1) MA42641A1 (es)
MX (2) MX2018005048A (es)
MY (1) MY192278A (es)
PE (1) PE20181167A1 (es)
PH (1) PH12018500873A1 (es)
PL (1) PL3365366T3 (es)
RS (1) RS62437B1 (es)
SG (1) SG11201803324VA (es)
SI (1) SI3365366T1 (es)
TW (3) TWI750139B (es)
UY (1) UY36965A (es)
WO (1) WO2017074878A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048770A2 (en) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
EP3778630A1 (en) * 2014-02-28 2021-02-17 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
WO2017079479A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
LT3443006T (lt) 2016-04-13 2023-10-25 Sanofi Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
US11845787B2 (en) * 2017-03-27 2023-12-19 The Wistar Institute Of Anatomy And Biology DNA antibody constructs for use against HIV
AR112257A1 (es) 2017-06-21 2019-10-09 Gilead Sciences Inc Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
BR112020007002A2 (pt) 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
US20240239877A1 (en) * 2017-12-18 2024-07-18 Viiv Healthcare Uk (No. 5) Limited Antigen binding polypeptides
JP7345861B2 (ja) * 2017-12-21 2023-09-19 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 二重特異性ｈｉｖ－１中和抗体
CN119291194A (zh) 2018-01-12 2025-01-10 建新公司 用于定量多肽的方法
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
JP7462621B2 (ja) * 2018-10-09 2024-04-05 サノフイ 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
US12459989B2 (en) * 2018-11-21 2025-11-04 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
EP3953388A1 (en) 2019-04-09 2022-02-16 Sanofi Trispecific binding proteins, methods, and uses thereof
WO2021080649A1 (en) 2019-10-25 2021-04-29 Sanofi Methods for analyzing chain mispairing in multispecific binding proteins
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
JP7518286B2 (ja) * 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118251411A (zh) * 2021-09-29 2024-06-25 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
CA3232365A1 (en) * 2021-09-29 2023-04-06 Ronnie Rong Wei Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv
WO2025109206A1 (en) 2023-11-22 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025108551A1 (en) 2023-11-23 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
US20250376537A1 (en) 2024-05-17 2025-12-11 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
US8637024B2 (en) 2010-11-12 2014-01-28 The Rockefeller University Fusion antibodies for HIV therapy
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN103797029B (zh) * 2011-05-17 2016-08-17 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
BR112014010823B1 (pt) 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
EP2788376B1 (en) 2011-12-08 2018-10-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AU2013322710A1 (en) * 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014089152A1 (en) 2012-12-04 2014-06-12 University Of Maryland, Baltimore Hiv-1 env-binding antibodies, fusion proteins, and methods of use
WO2014093894A2 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN105209491A (zh) 2013-03-15 2015-12-30 艾伯维公司 针对TNFα的双重特异性结合蛋白
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
EP3699195A3 (en) 2014-03-28 2020-11-04 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
CN106687584B (zh) 2014-09-04 2021-08-13 干细胞技术公司 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
WO2016187580A1 (en) 2015-05-20 2016-11-24 Quantum-Si Incorporated Method of determining the sequence of a nuclear acid using time resolved luminescence
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
MX2018003463A (es) 2015-09-22 2018-09-06 Univ Pennsylvania Método de redireccionamiento de células t para tratar la infección por virus de inmunodeficiencia humana (vih).
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
JP6732915B2 (ja) 2015-12-15 2020-07-29 ギリアード サイエンシーズ， インコーポレイテッド ヒト免疫不全ウイルス中和抗体
LT3443006T (lt) 2016-04-13 2023-10-25 Sanofi Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
WO2018120842A1 (zh) 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 一种双功能分子及其应用
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
US11845787B2 (en) 2017-03-27 2023-12-19 The Wistar Institute Of Anatomy And Biology DNA antibody constructs for use against HIV
BR112020007002A2 (pt) 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
JP7462621B2 (ja) 2018-10-09 2024-04-05 サノフイ 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
CL2018001065A1 (es) 2018-11-23
SG11201803324VA (en) 2018-05-30
CR20180288A (es) 2018-09-11
JP2021072847A (ja) 2021-05-13
IL258822B1 (en) 2023-04-01
CA3002664A1 (en) 2017-05-04
AR106466A1 (es) 2018-01-17
CN116789841A (zh) 2023-09-22
AU2016347058B2 (en) 2023-11-09
NZ781602A (en) 2025-07-25
UY36965A (es) 2017-05-31
EP3365366B1 (en) 2021-07-14
TW202442675A (zh) 2024-11-01
KR20180063336A (ko) 2018-06-11
WO2017074878A1 (en) 2017-05-04
JP7169190B2 (ja) 2022-11-10
CN116675776A (zh) 2023-09-01
MX2022014631A (es) 2023-01-11
US20220226495A1 (en) 2022-07-21
US20200054765A1 (en) 2020-02-20
US20250312475A1 (en) 2025-10-09
HK1253385A1 (zh) 2019-06-14
PH12018500873A1 (en) 2018-11-12
IL258822A (en) 2018-06-28
AU2016347058A1 (en) 2018-06-14
EA201891028A1 (ru) 2019-02-28
US11779651B2 (en) 2023-10-10
US20190054182A1 (en) 2019-02-21
JP2018537966A (ja) 2018-12-27
JP7328267B2 (ja) 2023-08-16
RS62437B1 (sr) 2021-11-30
MX2018005048A (es) 2018-09-06
MA42641A1 (fr) 2019-03-29
EP3819310A1 (en) 2021-05-12
CO2018005337A2 (es) 2018-07-10
MY192278A (en) 2022-08-16
NZ742825A (en) 2024-04-26
JP7724814B2 (ja) 2025-08-18
TW201730210A (zh) 2017-09-01
HRP20211528T1 (hr) 2021-12-24
TW202219064A (zh) 2022-05-16
CN117069855A (zh) 2023-11-17
AU2024200395A1 (en) 2024-04-11
PE20181167A1 (es) 2018-07-19
CN109311966A (zh) 2019-02-05
SI3365366T1 (sl) 2022-02-28
HUE056608T2 (hu) 2022-02-28
TWI750139B (zh) 2021-12-21
JP2023085476A (ja) 2023-06-20
IL301140A (en) 2023-05-01
PL3365366T3 (pl) 2022-01-31
IL258822B2 (en) 2023-08-01
EP3365366A1 (en) 2018-08-29
ES2894304T3 (es) 2022-02-14
KR102687212B1 (ko) 2024-07-19
BR112018008011A2 (en) 2018-10-30
CN109311966B (zh) 2023-03-10
US11129905B2 (en) 2021-09-28
WO2017074878A8 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
DOP2018000102A (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
PE20190128A1 (es) Proteinas de union triespecificas y/o trivalentes
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112018073761A2 (pt) proteínas de ligação ao cd3 de fragmento variável de cadeia única
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
BR112018012707A2 (pt) inibidores da interação de menin-mll
WO2015197598A3 (en) Multispecific antigen binding proteins
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
CO2021014988A2 (es) Proteínas de unión trispecificas y/o trivalentes utilizando el formato de dominio cruzado sobre dual variable (codv) para el tratamiento de la infección por vih
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
CO2017011583A2 (es) Polipéptidos dirigidos a la fusión de vih
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение
ECSP18039758A (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
AR118602A1 (es) Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih
AR113069A1 (es) VARIANTES DE ANTICUERPOS QUE SE UNEN A TNFa
ECSP18084491A (es) Proteínas de unión triespecíficas y/o trivalentes
EA202191078A2 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
AR108210A1 (es) Proteínas de unión triespecíficas y/o trivalentes